Comment Period Extended to 3/23/2015 for Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
24 studies found for:    EGFRvIII
Show Display Options
Rank Status Study
1 Recruiting CAR T Cell Receptor Immunotherapy Targeting EGFRvIII for Patients With Malignant Gliomas Expressing EGFRvIII
Conditions: Malignant Glioma;   Glioblastoma;   Brain Cancer
Interventions: Biological: Anti-EGFRvIII CAR transduced PBL;   Drug: Aldesleukin;   Drug: Fludarabine;   Drug: Cyclophosphamide
2 Recruiting Pilot Study of Autologous T Cells Redirected to EGFRVIII-With a Chimeric Antigen Receptor in Patients With EGFRVIII+ Glioblastoma
Condition: Patients With Residual or Reccurent EGFRvIII+ Glioma
Intervention: Biological: CART-EGFRvIII T cells
3 Active, not recruiting A Study of Rindopepimut/GM-CSF in Patients With Relapsed EGFRvIII-Positive Glioblastoma
Conditions: Glioblastoma;   Small Cell Glioblastoma;   Giant Cell Glioblastoma;   Gliosarcoma;   Glioblastoma With Oligodendroglial Component;   Recurrent Glioblastoma;   Relapsed Glioblastoma
Interventions: Drug: Bevacizumab;   Drug: Rindopepimut (CDX-110) with GM-CSF;   Drug: KLH
4 Recruiting Safety and Efficacy of PF-299804 (Dacomitinib), a Pan-HER Irreversible Inhibitor, in Patients With Recurrent Glioblastoma With EGFR Amplification or Presence of EGFRvIII Mutation. A Phase II CT.
Conditions: Glioblastoma;   Brain Tumor, Recurrent
Intervention: Drug: PF-299804 (Dacomitinib)
5 Active, not recruiting AMG 595 First-in-Human in Recurrent Gliomas
Conditions: Advanced Malignant Glioma;   Anaplastic Astrocytomas;   Glioblastoma Multiforme
Intervention: Drug: AMG 595
6 Active, not recruiting Phase III Study of Rindopepimut/GM-CSF in Patients With Newly Diagnosed Glioblastoma
Conditions: Glioblastoma;   Small Cell Glioblastoma;   Giant Cell Glioblastoma;   Gliosarcoma;   Glioblastoma With Oligodendroglial Component
Interventions: Drug: Rindopepimut (CDX-110) with GM-CSF;   Drug: Temozolomide;   Drug: KLH
7 Terminated Phase I Rindopepimut After Conventional Radiation in Children w/ Diffuse Intrinsic Pontine Gliomas
Conditions: Brain Cancer;   Brain Stem Tumors;   Pontine Tumors
Intervention: Biological: Rindopepimut
8 Terminated S0114 Vaccine Therapy in Treating Patients With Gastric, Prostate, or Ovarian Cancer
Conditions: Brain Tumors;   Gastric Cancer;   Ovarian Cancer;   Prostate Cancer
Interventions: Biological: KLH;   Biological: GMCSF
9 Active, not recruiting
Has Results
Vaccine Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme
Condition: Malignant Neoplasms of Brain
Interventions: Biological: PEP-3 vaccine;   Biological: sargramostim;   Drug: Temozolomide
10 Not yet recruiting D2C7 for Adult Patients With Recurrent Malignant Glioma
Conditions: Glioblastoma;   Glioma;   Malignant Glioma;   Brain Tumor, Recurrent
Intervention: Drug: D2C7-IT
11 Completed
Has Results
Phase (Ph) II Bevacizumab + Erlotinib for Patients (Pts) With Recurrent Malignant Glioma (MG)
Conditions: Glioblastoma;   Gliosarcoma
Intervention: Drug: Bevacizumab and Erlotinib
12 Active, not recruiting Phase II Study of Rindopepimut (CDX-110) in Patients With Glioblastoma Multiforme
Condition: Malignant Glioma
Interventions: Drug: CDX-110 with GM-CSF;   Drug: temozolomide
13 Terminated Erlotinib in Treating Patients With Progressive Glioblastoma Multiforme
Condition: Brain and Central Nervous System Tumors
Intervention: Drug: erlotinib hydrochloride
14 Recruiting Phase I Study of Safety and Immunogenicity of ADU-623
Conditions: Astrocytic Tumors;   Glioblastoma Multiforme;   Anaplastic Astrocytoma;   Brain Tumor
Interventions: Biological: Cohort 1;   Biological: Cohort 2;   Biological: Cohort 3;   Drug: Antibiotics
15 Completed Chemotherapy, Radiation Therapy, and Vaccine Therapy With Basiliximab in Treating Patients With Glioblastoma Multiforme That Has Been Removed by Surgery
Condition: Malignant Neoplasms of Brain
Interventions: Biological: PEP-3-KLH conjugate vaccine;   Biological: daclizumab;   Drug: temozolomide;   Other: placebo;   Biological: PEP-3-KLH
16 Active, not recruiting EGFR Inhibition Using High Dose Administration of Erlotinib Weekly for Recurrent Malignant Gliomas With EGFR Variant III Mutation
Condition: Brain Cancer
Intervention: Drug: erlotinib
17 Terminated Erlotinib Hydrochloride and Isotretinoin in Treating Patients With Recurrent Malignant Glioma
Conditions: Adult Anaplastic Astrocytoma;   Adult Anaplastic Oligodendroglioma;   Adult Diffuse Astrocytoma;   Adult Giant Cell Glioblastoma;   Adult Glioblastoma;   Adult Gliosarcoma;   Adult Mixed Glioma;   Adult Oligodendroglioma;   Recurrent Adult Brain Tumor
Interventions: Drug: erlotinib hydrochloride;   Drug: isotretinoin;   Other: laboratory biomarker analysis;   Genetic: protein expression analysis
18 Recruiting ABT-414 Alone or ABT-414 Plus Temozolomide vs. Lomustine or Temozolomide for Recurrent Glioblastoma
Condition: Glioblastoma Multiforme
Interventions: Drug: ABT-414;   Drug: Lomustine;   Drug: Temozolomide
19 Recruiting Oral Tarceva Study for Recurrent/Residual Glioblastoma Multiforme and Anaplastic Astrocytoma
Conditions: Glioblastoma Multiforme;   Anaplastic Astrocytoma
Intervention: Drug: Erlotinib
20 Completed PF-00299804 in Patients With Head and Neck Squamous Cell Carcinoma
Conditions: Head Neck Cancer Squamous Cell Metastatic;   Head Neck Cancer Squamous Cell Recurrent
Intervention: Drug: PF-00299804

   Previous Page Studies Shown (1-20) Next Page (21-24) Show next page of results    Last Page
Indicates status has not been verified in more than two years